Author: Ed Gover
CEO Rafiq Hasan describes to BiotechTV's Amy Brown during an interview in London how this program works, and he compares and contrasts it to more traditional therapies that are on the market currently. Plus, and overview of Complement's other programs and operations.
Please click here to read more
team of scientists from KTH Royal Institute of Technology and Karolinska Institutet has reported the development and characterization of a new class of small non-immunoglobulin affibody proteins that bind to the highly glycosylated human carcinoembryonic antigen-related adhesion molecule 5 (CEACAM5, CEA) with high affinity.
Please click here to subscribe and read the full story
Blind patients can read and recognise faces again with a “revolutionary” bionic chip, signalling a “new era” for artificial vision. The implant is an ultra-thin wireless microchip, measuring 2mm by 2mm, which is inserted under the retina and links to a video-camera fitted on a pair of augmented-reality glasses. Dozens of patients who lost their eyesight through age-related macular degeneration (AMD) were fitted with the device on a trial including Moorfields Hospital in London, with more than 80 per cent seeing major improvements.
About 600,000 people in the UK suffer from AMD, a number that is expected to increase with an ageing population, but there is currently no cure and the condition can be managed only with injections to slow the damage.
The device works with a video camera recording the scene in front of the patient, then AI is used to convert the information to an infrared signal that is beamed to the implant.
The implant stimulates undamaged inner retinal neurons, so they can transmit the signal to the brain, through the optic nerve, where it is interpreted as vision.
Biotechnology company Neumirna Therapeutics has announced its partnership with CDMO company ten23 health to advance treatments for epilepsy and other neurological diseases.
The companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring the therapy into clinical trials, combining ten23’s formulation and manufacturing expertise with Neumirna’s RNA innovation.
Please click here to read the full story
CPHI Frankfurt 2025:
New Trends Deliver Promise in OSDs from Core to Coating to Functional Packaging.
Click here to watch the video
Switzerland roots its foundations in life sciences collaboration
Switzerland hopes to establish its position as Europe's biotech partnership hub, attracting $3.1 billion in life sciences investment.
_(1).jpg?width=1280&auto=webp&quality=80&format=jpg&disable=upscale "Nordic Life Science Days in Gothenburg, Sweden - picture of people on stage")
“Culture eats strategy for breakfast,” Leif Johansson, AstraZeneca’s former chairman of the board, told the audience during a panel discussion at Nordic Life Science Days in Gothenburg, Sweden. The opening statement emphasised that organizational culture shapes innovation as much as, if not more than, business strategies.
Gerard Hendrik Hofstede, Dutch social psychologist, defined culture as “the collective programming of the mind which distinguishes the members of one group or category of people from another.”
Please click here to read more
Uppsala, Sweden October 23, 2025. Today, Dicot Pharma announces positive topline results from its phase 2a study of LIB-01 for the treatment of erectile dysfunction. The outcomes demonstrated clinically meaningful improvements in erectile function at week 4, following a single 3-day oral treatment with LIB-01. Furthermore, the effect was sustained at week 8 and showed statistical significance in one of the pre-specified subgroups. Treatment with LIB-01 remained well tolerated. Based on the results, Dicot Pharma will now proceed with the development of LIB-01 according to plan with initiation of a phase 2b study during 2026.
Dicot Pharma’s phase 2a study (NCT06703840) aimed to investigate the efficacy and safety of the drug candidate LIB-01 for treatment of erectile dysfunction (ED). The double-blind, placebo-controlled study included 156 men, ages 26 to 65, with mild to moderate ED, classified as 11–25 on the regulatory and clinically relevant International Index of Erectile Function - Erectile Function domain score (IIEF-EF). The trial evaluated LIB-01 at three different doses, 10 mg, 25 mg, and 50 mg. Participants were assessed at four and eight weeks to evaluate the effect of LIB-01.
Please click here to read more